Evidence map›Paper›PMID 27108931›Full record

ArticleNeuropharmacology2016

Compromising KCC2 transporter activity enhances the development of continuous seizure activity.

Matthew R Kelley, Tarek Z Deeb, Nicholas J Brandon, John Dunlop, Paul A Davies, Stephen J Moss

Abstract read
In one paragraph

Article in Neuropharmacology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.

0numbers the graph read from it
0cells of the map it votes in
26citing papers in PubMed
3.9field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

26 citing papers in PubMed, 48 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Article
  5. Article
  6. Neuronal KActa pharmacologica Sinica · 2024
    Review
  7. Article
  8. Review
  9. Review
  10. Article
  11. Discovery of Small Molecule KCC2 Potentiators Which AttenuateFrontiers in cell and developmental biology · 2022
    Article
  12. Review
  13. Review
  14. Article
  15. Article
  16. Article
  17. Pharmacological enhancement ofScience translational medicine · 2019
    Article
  18. Review
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 2 countries.

Matthew R KelleyDepartment of Neuroscience, Tufts University School of Medicine, Boston, MA 02111, USA.
Tarek Z DeebAstraZeneca Tufts Laboratory for Basic and Translational Neuroscience, Boston, MA 02111, USA.
Nicholas J BrandonAstraZeneca Neuroscience, Innovative Medicines and Early Development Biotech Unit, 141, Portland St, Cambridge, MA, USA.
John DunlopAstraZeneca Neuroscience, Innovative Medicines and Early Development Biotech Unit, 141, Portland St, Cambridge, MA, USA.
Paul A DaviesDepartment of Neuroscience, Tufts University School of Medicine, Boston, MA 02111, USA.
Stephen J MossDepartment of Neuroscience, Tufts University School of Medicine, Boston, MA 02111, USA; AstraZeneca Tufts Laboratory for Basic and Translational Neuroscience, Boston, MA 02111, USA; Department of Neuroscience, Physiology and Pharmacology, University College, London, WC1E 6BT, UK. Electronic address: Stephen.Moss@tufts.edu.
Tufts University · USAstraZeneca (United States) · US

Funding

Mechanisms that determine Glutamine synthetase activity in the brainR01NS081986 · NINDS · TUFTS UNIVERSITY BOSTON · PI MOSS, STEPHEN J · 2012 to 2022
$3.7M
Constructing inhibitory synapsesR01NS051195 · NINDS · UNIVERSITY OF PENNSYLVANIA · PI MOSS, STEPHEN J · 2006 to 2014
$3.2M
Modulation of KCC2 activity and the postnatal development of synaptic inhibitionR01NS101888 · NINDS · TUFTS UNIVERSITY BOSTON · PI DEEB, TAREK ZIAD, MOSS, STEPHEN J · 2017 to 2021
$2.3M
Dissecting Mechanisms of GABAB-GIRK Plasticity with PsychostimulantsR01DA037170 · NIDA · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI MOSS, STEPHEN J, SLESINGER, PAUL A · 2014 to 2018
$2.1M
Novel actions of neurosteroids on GABA (A) receptor traffickingR01MH097446 · NIMH · TUFTS UNIVERSITY BOSTON · PI DAVIES, PAUL ANDREW, MOSS, STEPHEN J · 2013 to 2017
$2.1M
Novel actions of neurosteroids on GABA (A) receptor traffickingR01NS108378 · NINDS · TUFTS UNIVERSITY BOSTON · PI DAVIES, PAUL ANDREW, MOSS, STEPHEN J · 2018 to 2022
$2.0M
Deficits in KCC2 activity and the pathophysiology of Status EpilepticusR01NS087662 · NINDS · TUFTS UNIVERSITY BOSTON · PI MOSS, STEPHEN J · 2014 to 2018
$2.0M
The role of ubiquitination in regulating GABA(A) receptor functional expressionR01NS056359 · NINDS · UNIVERSITY OF PENNSYLVANIA · PI MOSS, STEPHEN J · 2007 to 2010
$1.4M
Deficits in KCC2 activity and the pathophysiology of Autism spectrum disordersR21MH106954 · NIMH · TUFTS UNIVERSITY BOSTON · PI MOSS, STEPHEN J · 2015 to 2016
$454k
Mechanisms that determine the activity of glutamine synthetase in the brainR21NS103865 · NINDS · TUFTS UNIVERSITY BOSTON · PI MOSS, STEPHEN J · 2018 to 2019
$454k
Impaired KCC2 function underlies pharmacoresistant seizuresR21NS080064 · NINDS · TUFTS UNIVERSITY BOSTON · PI MOSS, STEPHEN J · 2013 to 2014
$452k
NIDA NIH HHS R01 DA037170NIMH NIH HHS R01 MH097446NIMH NIH HHS R21 MH106954NINDS NIH HHS R01 NS051195NINDS NIH HHS R01 NS056359NINDS NIH HHS R01 NS081986NINDS NIH HHS R01 NS087662NINDS NIH HHS R01 NS101888NINDS NIH HHS R01 NS108378NINDS NIH HHS R21 NS080064NINDS NIH HHS R21 NS103865
6 · The paper itself

Abstract

Impaired neuronal inhibition has long been associated with the increased probability of seizure occurrence and heightened seizure severity. Fast synaptic inhibition in the brain is primarily mediated by the type A γ-aminobutyric acid receptors (GABAARs), ligand-gated ion channels that can mediate Cl(-) influx resulting in membrane hyperpolarization and the restriction of neuronal firing. In most adult brain neurons, the K(+)/Cl(-) co-transporter-2 (KCC2) establishes hyperpolarizing GABAergic inhibition by maintaining low [Cl(-)]i. In this study, we sought to understand how decreased KCC2 transport function affects seizure event severity. We impaired KCC2 transport in the 0-Mg(2+) ACSF and 4-aminopyridine in vitro models of epileptiform activity in acute mouse brain slices. Experiments with the selective KCC2 inhibitor VU0463271 demonstrated that reduced KCC2 transport increased the duration of SLEs, resulting in non-terminating discharges of clonic-like activity. We also investigated slices obtained from the KCC2-Ser940Ala (S940A) point-mutant mouse, which has a mutation at a known functional phosphorylation site causing behavioral and cellular deficits under hyperexcitable conditions. We recorded from the entorhinal cortex of S940A mouse brain slices in both 0-Mg(2+) ACSF and 4-aminopyridine, and demonstrated that loss of the S940 residue increased the susceptibility of continuous clonic-like discharges, an in vitro form of status epilepticus. Our experiments revealed KCC2 transport activity is a critical factor in seizure event duration and mechanisms of termination. Our results highlight the need for therapeutic strategies that potentiate KCC2 transport function in order to decrease seizure event severity and prevent the development of status epilepticus.

Indexed as

4-AminopyridineAction PotentialsAnimalsHippocampusK Cl- CotransportersMaleMiceMice, Inbred C57BLOrgan Culture TechniquesSeizuresSymporters4-AminopyridineK Cl- CotransportersSymportersChloride transportEpilepsyGABAKCC2SeizureSLEStatus epilepticus

Identifiers

PMID27108931
PMCPMC5337122
OpenAlexW2341139437

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.